U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H37N5O2
Molecular Weight 451.6053
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CABERGOLINE

SMILES

C=CCN1C[C@@]([H])(C[C@]2([H])c3cccc4c3c(C[C@]21[H])c[nH]4)C(=O)N(CCCN(C)C)C(=NCC)O

InChI

InChIKey=KORNTPPJEAJQIU-KJXAQDMKSA-N
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/dosage/cabergoline.html http://www.wikidoc.org/index.php/Cabergoline http://www.rxlist.com/dostinex-drug.htm

Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. It is FDA approved for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Common adverse reactions include constipation, nausea, dizziness, headache and fatigue. Cabergoline should not be administered concurrently with D-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CABERGOLINE

Approved Use

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Launch Date

1.13581438E12
Primary
CABERGOLINE

Approved Use

Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Launch Date

1.13581438E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.3 ng/L
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
40.3 ng/L
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
67 ng/L
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12952 ng × h/L
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1884 ng × h/L
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2546 ng × h/L
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
68.54 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CABERGOLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
unknown, unknown
CABERGOLINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
L-dopa, po(370.6 mg)
Sources: Page: p.18, p.19, p.22
unhealthy, 41.0–73.5
n = 34
Health Status: unhealthy
Condition: Parkinson’s disease
Age Group: 41.0–73.5
Sex: M+F
Population Size: 34
Sources: Page: p.18, p.19, p.22
Sources: Page: p.18, p.19, p.22
2 mg 1 times / day multiple, oral (min)
Overdose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Parkinson’s disease
Sources: Page: p.4
Other AEs: Cardiac valvulopathy...
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources: Page: p.9
unhealthy
n = 221
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Population Size: 221
Sources: Page: p.9
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (1.4%)
Nausea (0.9%)
Vomiting (0.9%)
Sources: Page: p.9
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources: Page: p.4
Disc. AE: Pleural effusion, Pulmonary fibrosis...
Other AEs: Cardiac valvulopathy, Pericardial fibrosis...
AEs leading to
discontinuation/dose reduction:
Pleural effusion
Pulmonary fibrosis
Other AEs:
Cardiac valvulopathy
Pericardial fibrosis
Retroperitoneal fibrosis
Sources: Page: p.4
AEs

AEs

AESignificanceDosePopulation
Cardiac valvulopathy
2 mg 1 times / day multiple, oral (min)
Overdose
Dose: 2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2 mg, 1 times / day
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Parkinson’s disease
Sources: Page: p.4
Nausea 0.9%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources: Page: p.9
unhealthy
n = 221
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Population Size: 221
Sources: Page: p.9
Vomiting 0.9%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources: Page: p.9
unhealthy
n = 221
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Population Size: 221
Sources: Page: p.9
Headache 1.4%
Disc. AE
0.5 mg 2 times / week multiple, oral
Recommended
Dose: 0.5 mg, 2 times / week
Route: oral
Route: multiple
Dose: 0.5 mg, 2 times / week
Sources: Page: p.9
unhealthy
n = 221
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Population Size: 221
Sources: Page: p.9
Cardiac valvulopathy
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources: Page: p.4
Pericardial fibrosis
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources: Page: p.4
Retroperitoneal fibrosis
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources: Page: p.4
Pleural effusion Disc. AE
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources: Page: p.4
Pulmonary fibrosis Disc. AE
1 mg 2 times / week multiple, oral (max)
Recommended
Dose: 1 mg, 2 times / week
Route: oral
Route: multiple
Dose: 1 mg, 2 times / week
Sources: Page: p.4
unhealthy
Health Status: unhealthy
Condition: Hyperprolactinemic disorders
Sources: Page: p.4
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: n healthy male volunteers, the mean of Cmax and AUC of cabergoline increased around 2.7 times by coadministration of clarithromycin.
Page: -
PubMed

PubMed

TitleDatePubMed
Bait-delivered cabergoline for the reproductive control of the red fox (Vulpes vulpes): estimating mammalian non-target risk in south-eastern Australia.
2001
Prolactinomas in children and adolescents--consequences in adult life.
2001
Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
2001 Aug
Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.
2001 Aug
A review of canine pseudocyesis.
2001 Dec
Medical management of prolactin-secreting pituitary adenomas.
2002
[Use of dopamine agonists in the treatment of Parkinson's disease].
2002
Assessment of cabergoline as a reproductive inhibitor in coyotes (Canis latrans).
2002
DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease.
2002
Control of fertility in the red fox (Vulpes vulpes): effect of a single oral dose of cabergoline in early pregnancy.
2002
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
2002
Pregnancy termination in the bitch and queen.
2002 Aug
Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
2002 Dec
Alopecia induced by dopamine agonists.
2002 Dec 24
A case of macroprolactinoma with subclinical growth hormone production.
2002 Feb
Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline.
2002 Feb
Restless legs syndrome: treatment with dopaminergic agents.
2002 Feb 26
Long-term studies of dopamine agonists.
2002 Feb 26
The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals.
2002 Jul
Gateways to clinical trials.
2002 Jul-Aug
Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
2002 Jul-Aug
Dopamine receptor agonists for treating prolactinomas.
2002 Jun
Use of cabergoline to treat primary and secondary anestrus in dogs.
2002 Jun 1
SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks.
2002 Jun 11
Sleep attacks in patients taking dopamine agonists: review.
2002 Jun 22
Hyperprolactinemia: etiology, diagnosis, and management.
2002 Nov
Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
2002 Nov
Effect of cabergoline on thyroid function in hyperprolactinaemia.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
Dopamine agonist monotherapy in Parkinson's disease.
2002 Nov 30
Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy.
2002 Oct
An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
2002 Oct
Use of the dopamine agonist cabergoline in the treatment of movement disorders.
2002 Oct
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
2002 Oct
A practical synthesis of cabergoline.
2002 Oct 4
Combination of two different dopamine agonists in the management of Parkinson's disease.
2002 Sep
Gateways to Clinical Trials.
2002 Sep
Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment.
2002 Sep
Accurate mass measurement at enhanced mass-resolution on a triple quadrupole mass-spectrometer for the identification of a reaction impurity and collisionally-induced fragment ions of cabergoline.
2003
Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.
2003 Feb
Radioimmunoassay of prolactin for the meerkat (Suricata suricatta), a cooperatively breeding carnivore.
2003 Feb 1
Hyperprolactinemia in men: clinical and biochemical features and response to treatment.
2003 Feb-Mar
[Efficacy of cabergoline in the treatment of macroprolactinoma].
2003 Jan 18
Involvement of PI3'-K, mitogen-activated protein kinase and protein kinase B in the up-regulation of the expression of nNOSalpha and nNOSbeta splicing variants induced by PRL-receptor activation in GH3 cells.
2003 Mar
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
2003 Mar
Prolactinomas, dopamine agonists and headache: two case reports.
2003 Mar
Selective control of the estrous cycle of the dog through suppression of estrus and reduction of the length of anestrus.
2003 Mar
[Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
2003 Mar 28
Patents

Sample Use Guides

The recommended dosage for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks.
Route of Administration: Oral
Tert-butylhydroperoxide caused a 42+/-4% neuronal death, which was prevented by cabergoline (2 h before) in a concentration-dependent manner (EC(50): 1.24 microM).
Name Type Language
CABERGOLINE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
FCE-21336
Code English
DOSTINEX
Brand Name English
CABERGOLINE [JAN]
Common Name English
CABERGOLINE [VANDF]
Common Name English
VELACTIS
Brand Name English
CABASER
Brand Name English
CABERGOLINE [USP-RS]
Common Name English
ERGOLINE-8.BETA.-CARBOXAMIDE, N-(3-(DIMETHYLAMINO)PROPYL)-N-((ETHYLAMINO)CARBONYL)-6-(2-PROPENYL)-
Systematic Name English
CABERGOLINE [ORANGE BOOK]
Common Name English
FCE 21336
Code English
CABERGOLINE [USAN]
Common Name English
1-((6-ALLYLERGOLIN-8.BETA.-YL)CARBONYL)-1-(3-(DIMETHYLAMINO)PROPYL)-3-ETHYLUREA
Systematic Name English
CABERGOLINE [WHO-DD]
Common Name English
CABERGOLINE [EP MONOGRAPH]
Common Name English
CABERGOLINE [INN]
Common Name English
CABERGOLINE [MI]
Common Name English
CABERGOLINE [MART.]
Common Name English
CABERGOLINE [USP MONOGRAPH]
Common Name English
CABERGOLINE [EMA EPAR VETERINARY]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66884
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
NCI_THESAURUS C38149
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
WHO-VATC QG02CB03
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
WHO-ATC N04BC06
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
NDF-RT N0000007618
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
LIVERTOX 135
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
WHO-VATC QN04BC06
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
NDF-RT N0000175827
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
WHO-ATC G02CB03
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
NDF-RT N0000007618
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
EMA VETERINARY ASSESSMENT REPORTS VELACTIS [SUSPENDED]
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL1201087
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
DRUG CENTRAL
460
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
MESH
C047047
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
WIKIPEDIA
CABERGOLINE
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
CAS
81409-90-7
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
IUPHAR
37
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
NCI_THESAURUS
C47428
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
INN
5860
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
EPA CompTox
81409-90-7
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
RXCUI
47579
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY RxNorm
PUBCHEM
54746
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
LACTMED
Cabergoline
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
USP_CATALOG
1084306
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY USP-RS
EVMPD
SUB06041MIG
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
DRUG BANK
DB00248
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
FDA UNII
LL60K9J05T
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY
MERCK INDEX
M2876
Created by admin on Fri Jun 25 21:05:43 UTC 2021 , Edited by admin on Fri Jun 25 21:05:43 UTC 2021
PRIMARY Merck Index